Effectiveness of the AML-XH-99-M3 protocol for treatment of acute promyelocytic leukemia in children
DOI:
CSTR:
Author:
Affiliation:

Clc Number:

R733.71

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    OBJECTIVE: To evaluate the effectiveness of AML-XH-99-M3 protocol for treatment of acute promyelocytic leukemia (APL) in children.METHODS: Thirty-three children with APL received AML-XH-99-M3 protocol treatment. The event-free survival (EFS), disease-free survival (DFS), and overall survival (OS) were evaluated by the Kaplan-Meier medthod with SPSS13.0 software.RESULTS: Thirty patients (90.9%) achieved a complete remission (CR) after one course of treatment. The total CR rate was 100%. Six patients (18.2%) relapsed in an average of 29.17 months (16-38 months). Two patients (6.1%) died. The 7-year EFS and DFS in the 30 patients were 73.4±9.4%. The overall survival rate was 91.2±6.0%. The difference of EFS was observed in patients receiving intermittent all-trans-retinoic acid (ATRA) administration or not in the maintenance therapy (88.9±10.5% vs 62.5±13.6%) (P<0.05).CONCLUSIONS: The AML-XH-99-M3 protocol for the treatment of APL produced a higher CR rate and higher EFS, DFS and OS rates in children. Intermittent administration of ATRA in the maintenance therapy can improve EFS rate.

    Reference
    Related
    Cited by
Get Citation

陈静, 顾龙君, 汤静燕, 薛惠良, 潘慈, 叶启东, 江华, 董璐, 周敏, 王耀平. AML-XH-99-M3 方案治疗33例儿童急性早幼粒细胞白血病临床总结[J].中国当代儿科杂志英文版,2008,10(3):329-332

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:
  • Revised:
  • Adopted:
  • Online: September 08,2009
  • Published:
Article QR Code